Exchange: NASDAQ·Updated 04:10 PM EDT

BRVE Braveheart Bio Inc.

$27.45
$0.74
(2.77%)
Today
Closed $27.45
$0.00
(0.00%)
After Hours
Reported EarningsSep 8
Mkt Cap$2.4B
Vol550,667.00

About BRVE

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
48

Neutral Sentiment

How do you feel about BRVE?

Advertisement|Remove ads.